logo

GOVX

GeoVax Labs·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

GOVX fundamentals

GeoVax Labs (GOVX) released its earnings on Nov 13, 2025: revenue was 0 (YoY -100.00%), beat estimates; EPS was -0.31 (YoY +65.93%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.31
+65.93%
Report date
Nov 13, 2025
GOVX Earnings Call Summary for Q3,2025
  • GEO-MVA Milestone: EMA guidance enables Phase III trial, with clinical manufacturing underway for early 2026 evaluation.
  • CM04S1 Promise: Phase II data shows potential for immunocompromised patients, aligning with IDSA guidelines.
  • Financial Focus: $5M cash balance supporting key programs, with exploration of nondilutive funding to extend runway.
  • Strategic Growth: Increased collaboration interest for MVA supply chain and oncology partnerships.
  • Risk Management: Net loss up 2% YoY due to clinical costs, but cost control efforts maintained R&D efficiency.
EPS
Revenue

Revenue & Expenses

Key Indicators

GeoVax Labs (GOVX) key financial stats and ratios, covering profitability, financial health, and leverage.
GeoVax Labs (GOVX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
GeoVax Labs (GOVX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
GeoVax Labs (GOVX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does GeoVax Labs (GOVX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track GeoVax Labs (GOVX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield